It could be speculated that small siderophore-mimic compounds or NGAL/receptors disruptors, easily conveyable to tumor microenvironment, could be used to block NGAL activity in neutrophils, macrophages, fibroblasts and endothelial cells other than in cancer cells. Here, LCN2 is linked to cancer.